Related references
Note: Only part of the references are listed.Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies
Siba P. Raychaudhuri et al.
JOURNAL OF AUTOIMMUNITY (2017)
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
L. Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial
Michael E. Weinblatt et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis
Giampiero Girolomoni et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2012)
Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment
L. C. Coates et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
E. C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Golimumab, a New Human Tumor Necrosis Factor α Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study
Arthur Kavanaugh et al.
ARTHRITIS AND RHEUMATISM (2009)
Golimumab, a Human Anti-Tumor Necrosis Factor α Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis Twenty-Four-Week Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Golimumab Before Methotrexate as First-Line Therapy for Early-Onset Rheumatoid Arthritis
Paul Emery et al.
ARTHRITIS AND RHEUMATISM (2009)
Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis
Paul J. Healy et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
Robert D. Inman et al.
ARTHRITIS AND RHEUMATISM (2008)
Treatment choices, preferences and decision-making by patients with rheumatoid arthritis
Frances Chilton et al.
MUSCULOSKELETAL CARE (2008)
Classification criteria for psoriatic arthritis - Development of new criteria from a large international study
William Taylor et al.
ARTHRITIS AND RHEUMATISM (2006)
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2005)
Psoriatic arthritis imaging: a review of scoring methods
D van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Etanercept treatment of psoriatic arthritis - Safety, efficacy, and effect on disease progression
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2004)
Share Paper
